TY  - JOUR
AU  - Glemser, Philip Alexander
AU  - Rotkopf, Lukas Thomas
AU  - Ziener, Christian
AU  - Beuthien-Baumann, Bettina
AU  - Weru, Vivienn
AU  - Kopp-Schneider, Annette
AU  - Schlemmer, Heinz-Peter
AU  - Dimitrakopoulou-Strauss, Antonia
AU  - Sachpekidis, Christos
TI  - Hybrid imaging with [68Ga]PSMA-11 PET-CT and PET-MRI in biochemically recurrent prostate cancer.
JO  - Cancer imaging
VL  - 22
IS  - 1
SN  - 1470-7330
CY  - London
M1  - DKFZ-2022-02260
SP  - 53
PY  - 2022
N1  - #EA:E010#LA:E060#
AB  - To compare [68Ga]PSMA-11 PET-CT, [68Ga]PSMA-11 PET-MRI and MRI in a cohort of prostate cancer (PCa) patients in biochemical recurrence after initial curative therapy.Fifty-three patients with biochemically recurrent PCa underwent whole-body [68Ga]PSMA-11 PET-CT 1 hour post-injection (p.i.) followed by [68Ga]PSMA-11 PET-MRI 2.5 hours p.i., including a multiparametric MRI pelvic protocol examination. Imaging data analysis consisted of visual (qualitative) evaluation of the PET-CT, PET-MRI and MRI scans, as well as semi-quantitative and quantitative analyses of the PET and MRI data, including calculation of the parameters standardized uptake value (SUV) and apparent diffusion coefficient (ADC) derived from the PCa lesions. Association analysis was performed between imaging and clinical data, including PSA level and Gleason score. The results were considered significant for p-values less than 0.05 (p < 0.05).The hybrid imaging modalities [68Ga]PSMA-11 PET-CT and PET-MRI were positive in more patients than MRI alone. In particular, PET-CT detected lesions suggestive of PCa relapse in 34/53 (64.2
KW  - ADC (Other)
KW  - PET-CT (Other)
KW  - PET-MRI (Other)
KW  - Prostate cancer recurrence (Other)
KW  - SUV (Other)
KW  - [68Ga]PSMA-11 ligand (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:36138437
DO  - DOI:10.1186/s40644-022-00489-9
UR  - https://inrepo02.dkfz.de/record/181845
ER  -